{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T21:17:10Z","timestamp":1794691030439,"version":"4.9.1"},"reference-count":27,"publisher":"American Society of Hematology","issue":"23","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Lisocabtagene maraleucel (liso-cel) has shown promising efficacy in clinical trials for patients with relapsed\/refractory large B-cell lymphoma (LBCL). We present health-related quality of life (HRQOL) results from the TRANSFORM study, the first comparative analysis of liso-cel vs standard of care (SOC) as second-line therapy in this population. Adults with LBCL refractory or relapsed \u226412 months after first-line therapy and eligible for autologous stem cell transplantation were randomized 1:1 to the liso-cel or SOC arms (3 cycles of immunochemotherapy in which responders proceeded to high-dose chemotherapy and autologous stem cell transplantation). HRQOL was assessed by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire \u2013 30 items and the Functional Assessment of Cancer Therapy-Lymphoma subscale. Patients with baseline and \u22651 postbaseline assessment were analyzed (liso-cel, n\u00a0= 47; SOC, n\u00a0= 43). The proportion of patients with meaningful improvement in global health status\/quality of life (QOL) was higher, whereas deterioration was lower in the liso-cel arm vs SOC arm from day 126 to month 6. Mean change scores showed meaningful worsening in global health status\/QOL at month 6, fatigue at day 29 and month 6, and pain at month 6 with SOC; mean scores for other domains were maintained or improved in both arms. Time to confirmed deterioration favored the liso-cel arm vs SOC arm in global health status\/QOL (median: not reached vs 19.0 weeks, respectively; hazard ratio, 0.47; 95% confidence interval, 0.24-0.94). HRQOL was either improved or maintained from baseline in patients with relapsed\/refractory LBCL in the liso-cel arm vs SOC arm as second-line treatment. This study is registered at clinicaltrials.gov as #NCT0357531.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022008106","type":"journal-article","created":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T18:00:47Z","timestamp":1663956047000},"page":"5969-5979","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":27,"title":["Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL"],"prefix":"10.1182","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8467-9257","authenticated-orcid":false,"given":"Jeremy S.","family":"Abramson","sequence":"first","affiliation":[{"name":"1Lymphoma Program, Massachusetts General Hospital Cancer Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick B.","family":"Johnston","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manali","family":"Kamdar","sequence":"additional","affiliation":[{"name":"3Division of Hematology, Hematologic Malignancies and Stem Cell Transplantation, University of Colorado Cancer Center, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami","family":"Ibrahimi","sequence":"additional","affiliation":[{"name":"4Transplant and Cellular Therapy Clinic, University of Oklahoma Stephenson Cancer Center, Oklahoma City, OK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Izutsu","sequence":"additional","affiliation":[{"name":"5Department of Hematology, National Cancer Center Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Arnason","sequence":"additional","affiliation":[{"name":"6Department of Hematology\/Oncology, Beth Israel Deaconess Medical Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertram","family":"Glass","sequence":"additional","affiliation":[{"name":"7Department of Hematology and Cell Therapy, Helios Klinikum Berlin-Buch, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pim","family":"Mutsaers","sequence":"additional","affiliation":[{"name":"8Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Lunning","sequence":"additional","affiliation":[{"name":"9Hematology\/Oncology Division, University of Nebraska Medical Center, Omaha, NE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Braverman","sequence":"additional","affiliation":[{"name":"10Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3364-0808","authenticated-orcid":false,"given":"Fei Fei","family":"Liu","sequence":"additional","affiliation":[{"name":"10Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Crotta","sequence":"additional","affiliation":[{"name":"11Celgene, a Bristol-Myers Squibb Company, Boudry, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Montheard","sequence":"additional","affiliation":[{"name":"11Celgene, a Bristol-Myers Squibb Company, Boudry, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Previtali","sequence":"additional","affiliation":[{"name":"11Celgene, a Bristol-Myers Squibb Company, Boudry, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shien","family":"Guo","sequence":"additional","affiliation":[{"name":"12Clinical Outcome Assessment, Evidera, Waltham, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Shi","sequence":"additional","affiliation":[{"name":"12Clinical Outcome Assessment, Evidera, Waltham, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott R.","family":"Solomon","sequence":"additional","affiliation":[{"name":"13Transplant and Cellular Immunotherapy Program, Northside Hospital Cancer Institute, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,11,30]]},"reference":[{"issue":"1","key":"2023053018335168500_bib1","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1182\/blood-2014-05-575092","article-title":"Primary mediastinal B-cell lymphoma and mediastinal gray zone lymphoma: do they require a unique therapeutic approach?","volume":"125","author":"Dunleavy","year":"2015","journal-title":"Blood"},{"issue":"1","key":"2023053018335168500_bib2","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2014-04-516815","article-title":"Transformed follicular non-Hodgkin lymphoma","volume":"125","author":"Casulo","year":"2015","journal-title":"Blood"},{"issue":"1","key":"2023053018335168500_bib3","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2014-05-577189","article-title":"Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity","volume":"125","author":"Sehn","year":"2015","journal-title":"Blood"},{"issue":"27","key":"2023053018335168500_bib4","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"31","key":"2023053018335168500_bib5","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1200\/JCO.2013.53.9593","article-title":"Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12","volume":"32","author":"Crump","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2023053018335168500_bib6","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/bmt.2015.213","article-title":"Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study","volume":"51","author":"Van Den Neste","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"2023053018335168500_bib7","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1200\/JCO.2016.69.0198","article-title":"Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: the ORCHARRD study","volume":"35","author":"van Imhoff","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"52","key":"2023053018335168500_bib8","doi-asserted-by":"crossref","first-page":"29843","DOI":"10.18632\/oncotarget.25688","article-title":"CD19 directed CAR T cell therapy in diffuse large B-cell lymphoma","volume":"9","author":"Quintas-Cardama","year":"2018","journal-title":"Oncotarget"},{"issue":"10254","key":"2023053018335168500_bib9","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"2023053018335168500_bib10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"1","key":"2023053018335168500_bib11","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"10343","key":"2023053018335168500_bib12","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","article-title":"Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"key":"2023053018335168500_bib13","unstructured":"Efficacy of axicabtagene ciloleucel compared to standard of care therapy in subjects with relapsed\/refractory diffuse large B cell lymphoma (ZUMA-7). ClinicalTrials.gov identifier: NCT03391466. Updated 29 April 2022. Accessed 22 November 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT03391466."},{"issue":"21","key":"2023053018335168500_bib14","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.1182\/blood.V120.21.4287.4287","article-title":"Health-related quality of life in older patients following diffuse large B-cell lymphoma (DLBCL) diagnosis","volume":"120","author":"Kelly","year":"2012","journal-title":"Blood"},{"issue":"suppl 1","key":"2023053018335168500_bib15","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1182\/blood-2018-99-112878","article-title":"The burden of relapsed\/refractory (R\/R) diffuse large B-cell lymphoma (DLBCL): a systematic literature review (SLR)","volume":"132","author":"Lenz","year":"2018","journal-title":"Blood"},{"issue":"15 suppl","key":"2023053018335168500_bib16","doi-asserted-by":"crossref","first-page":"e20070","DOI":"10.1200\/JCO.2020.38.15_suppl.e20070","article-title":"Health-related quality of life (HRQOL) burden in patients with relapsed\/refractory diffuse large B-cell lymphoma (RR-DLBCL) and non-Hodgkin\u2019s lymphoma (RRNHL)","volume":"38","author":"Lin","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"2023053018335168500_bib17","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1182\/bloodadvances.2020003503","article-title":"Effect of lisocabtagene maraleucel on HRQoL and symptom severity in relapsed\/refractory large B-cell lymphoma","volume":"5","author":"Patrick","year":"2021","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2023053018335168500_bib18","doi-asserted-by":"crossref","first-page":"3845","DOI":"10.1182\/blood-2021-151611","article-title":"Improved quality of life with lisocabtagene maraleucel, a CD19-directed chimeric antigen receptor T cell therapy, compared with standard of care as second-line treatment in patients with relapsed or refractory large B-cell lymphoma: results from the phase 3 TRANSFORM study","volume":"138","author":"Abramson","year":"2021","journal-title":"Blood"},{"issue":"5","key":"2023053018335168500_bib19","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"11","key":"2023053018335168500_bib20","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.ejca.2012.02.059","article-title":"Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30","volume":"48","author":"Cocks","year":"2012","journal-title":"Eur J Cancer"},{"issue":"1","key":"2023053018335168500_bib21","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1200\/JCO.2010.28.0107","article-title":"Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30","volume":"29","author":"Cocks","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"2023053018335168500_bib22","author":"Cocks","year":"2015"},{"issue":"6","key":"2023053018335168500_bib23","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.ejon.2013.05.006","article-title":"EORTC QLQ-C30 and FACT-Lym for the assessment of health-related quality of life of newly diagnosed lymphoma patients undergoing chemotherapy","volume":"17","author":"Georgakopoulos","year":"2013","journal-title":"Eur J Oncol Nurs"},{"key":"2023053018335168500_bib24","doi-asserted-by":"crossref","first-page":"147176","DOI":"10.1155\/2013\/147176","article-title":"The development and validation of a measure of health-related quality of life for non-Hodgkin\u2019s lymphoma: the Functional Assessment of Cancer Therapy\u2014Lymphoma (FACT-Lym)","volume":"2013","author":"Hlubocky","year":"2013","journal-title":"Lymphoma"},{"key":"2023053018335168500_bib25","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ejca.2018.11.024","article-title":"General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the Unites States","volume":"107","author":"Nolte","year":"2019","journal-title":"Eur J Cancer"},{"issue":"1","key":"2023053018335168500_bib26","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s40487-021-00174-0","article-title":"Patient perspectives on health-related quality of life in diffuse large B-cell lymphoma treated with Car T-cell therapy: a qualitative study","volume":"10","author":"Cheng","year":"2022","journal-title":"Oncol Ther"},{"issue":"10","key":"2023053018335168500_bib27","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/bmt.2010.304","article-title":"A\u00a0prospective evaluation of patients' health-related quality of life during auto-SCT: a 3-year follow-up","volume":"46","author":"Frodin","year":"2011","journal-title":"Bone Marrow Transplant"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/23\/5969\/2054112\/blooda_adv-2022-008106-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/23\/5969\/2054112\/blooda_adv-2022-008106-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T18:34:16Z","timestamp":1685471656000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/23\/5969\/486699\/Health-related-quality-of-life-with-lisocabtagene"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,30]]},"references-count":27,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2022,12,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022008106","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,30]]}}}